Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism
Farge-Bancel, Dominique (Assistance publique - Hôpitaux de Paris (França))
Trujillo-Santos, Javier (Hospital General Universitario Santa Lucía (Cartagena, Múrcia))
Debourdeau, Philippe (Institut Sainte Catherine (Avignon, França))
Bura-Riviere, Alessandra (Hôpital Rangueil (Toulouse, França))
Rodriguez-Beltrán, Eva María (Hospital Nuestra Señora de Sonsoles (Àvila))
Nieto, José Antonio (Hospital Virgen de La Luz (Cuenca))
Peris, María Luisa (Consorci Hospitalari Provincial de Castelló)
Zeltser, David (Tel Aviv Sourasky Medical Center (Israel))
Mazzolai, Lucia (Centre Hospitalier Universitaire Vaudois (Lausanne, Suïssa))
Hij, Adrian (Assistance publique - Hôpitaux de Paris (França))
Monreal, Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
RIETE Investigators

Data:	2015
Resum:	In cancer patients treated for venous thromboembolism (VTE), including deep-vein thrombosis (DVT) and pulmonary embolism (PE), analyzing mortality associated with recurrent VTE or major bleeding is needed to determine the optimal duration of anticoagulation. This was a cohort study using the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) Registry database to compare rates of fatal recurrent PE and fatal bleeding in cancer patients receiving anticoagulation for VTE. As of January 2013, 44,794 patients were enrolled in RIETE, of whom 7911 (18%) had active cancer. During the course of anticoagulant therapy (mean, 181 ± 210 days), 178 cancer patients (4. 3%) developed recurrent PE (5. 5 per 100 patient-years; 95% CI: 4. 8-6. 4), 194 (4. 7%) had recurrent DVT (6. 2 per 100 patient-years; 95% confidence interval [CI]: 5. 3-7. 1), and 367 (8. 9%) bled (11. 3 per 100 patient-years; 95% CI: 10. 2-12. 5). Of 4125 patients initially presenting with PE, 43 (1. 0%) died of recurrent PE and 45 (1. 1%) of bleeding; of 3786 patients with DVT, 19 (0. 5%) died of PE, and 55 (1. 3%) of bleeding. During the first 3 months of anticoagulation, there were 59 (1. 4%) fatal PE recurrences and 77 (1. 9%) fatal bleeds. Beyond the third month, there were 3 fatal PE recurrences and 23 fatal bleeds. In RIETE cancer patients, the rate of fatal recurrent PE or fatal bleeding was much higher within the first 3 months of anticoagulation therapy.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Medicine, Vol. 94 Núm. 32 (august 2015) , ISSN 1536-5964

DOI: 10.1097/MD.0000000000001235
PMID: 26266353

10 p, 421.6 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats